Dyne Therapeutics, citing trial data, said it will ask the FDA to approve DYNE-251, its therapy for DMD amenable to exon 51 skipping.

During this season of hope, columnist Robin Stemple shares his wishes for both the disability community and himself.

Experimental therapy deramiocel outperformed a placebo at improving measures of arm and heart health in people with DMD in a ...

Columnist Patrick Moeschen argues that we all should focus more on finding the right words to accurately describe living with ...

Columnist Betty Vertin is planning a holiday season this year that will let her sons with DMD better enjoy their time with family and friends.

Upsher-Smith Laboratories launched DMD treatment Kymbee in the U.S., backed by a support program for patients.

Columnist Shalom Lim attended a musical honoring healthcare professionals and, as someone with Duchenne MD, came away feeling ...

A regimen of three immune-suppressing drugs may improve the effectiveness of gene therapy for people with DMD, research in ...

The holiday season is upon us, and I am already exhausted. I’m well aware of everything I need to do in December, so being this tired already isn’t great. It makes me think about the opening lines of ...